# US 2010/0143298 A1 · Colloidal metal compositions and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0143298 A1
- Document ID: US20100143298A1
- Status: Published application
- Kind: A1
- Application number: 12/708,326
- Filed: 2010-02-18
- Published: 2010-06-10
- Earliest claimed: 2001-04-30
- Assignees: CytImmune Sciences, Inc.
- Inventors: LAWRENCE TAMARKIN; Giulio F. Paciotti
- Web page: https://patentgrep.com/patent/US20100143298A1

## CPC

- C07K 14/525: Tumour necrosis factor [TNF]
- A61K 38/191: {Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta}
- A61K 38/39: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/6923: {the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb}
- A61K 49/0013: {Luminescence}
- A61K 49/0017: {Fluorescence in vivo}
- A61K 49/0056: {Peptides, proteins, polyamino acids}
- A61K 49/0065: {the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle}
- A61K 51/1244: {microparticles or nanoparticles, e.g. polymeric nanoparticles}
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 37/04: Immunostimulants
- C07K 16/241: {Tumor Necrosis Factors}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/55522: {Cytokines; Lymphokines; Interferons}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention comprises compositions and methods for delivery systems of agents, including therapeutic compounds, pharmaceutical agents, drugs, detection agents, nucleic acid sequences and biological factors. In general, these vector compositions comprise a colloidal metal, derivatized PEG (polyethylene glycol) and an agent. The invention also comprises methods and compositions for making such colloidal metal compositions and for treatment of cancer.

## Claims

### Claim 1

A vector composition, comprising, a colloidal metal particle, at least one agent, and PEG derivative.

### Claim 2 (depends on 1)

The vector composition of claim 1, further comprising a targeting molecule.

### Claim 3 (depends on 1)

The vector composition of claim 1, further comprising an integrating molecule.

### Claim 4 (depends on 1)

The vector composition of claim 1, wherein the at least one agent is TNF, tumor necrosis factor.

### Claim 5 (depends on 1)

The vector composition of claim 1, wherein the PEG derivative is a thiol derivative.

### Claim 6 (depends on 1)

The vector composition of claim 1, further comprising a component-specific immunostimulating molecule.

### Claim 7 (depends on 6)

The vector composition of claim 6, wherein the component-specific immunostimulating molecule comprises at least one of Interleukin-1 (“IL-1”), Interleukin-2 (“IL-2”), Interleukin-3 (“IL-3”), Interleukin-4 (“IL-4”), Interleukin-5 (“IL-5”), Interleukin-6 (“IL-6”), Interleukin-7 (“IL-7”), Interleukin-8 (“IL-8”), Interleukin-10 (“IL-10”), Interleukin-11 (“IL-11”), Interleukin-12 (“IL-12”), Interleukin-13 (“IL-13”), lipid A, phospholipase A2, endotoxins, staphylococcal enterotoxin B and other toxins, Type I Interferon, Type II Interferon, Tumor Necrosis Factor (“TNF-”), Transforming Growth Factor-β (“TGF-β”. Lymphotoxin, Migration Inhibition Factor, Granulocyte-Macrophage Colony-Stimulating Factor (“CSF”), Monocyte-Macrophage CSF, Granulocyte CSF, vascular epithelial growth factor (“VEGF”), Angiogenin, transforming growth factor (“TGF-”), heat shock proteins, carbohydrate moieties of blood groups, Rh factors, fibroblast growth factor, and other inflammatory and immune regulatory proteins, nucleotides, DNA, RNA, mRNA, sense, antisense, cancer cell specific antigens; such as MART, MAGE, BAGE, and HSPs; flt3 ligand/receptor system; B7 family of molecules and receptors; CD 40 ligand/receptor; and immunotherapy drugs, such as AZT; and angiogenic and anti-angiogenic drugs, such as angiostatin, endostatin, and basic fibroblast growth factor, or vascular endothelial growth factor (VEGF).

### Claim 8

A method of delivering an agent, comprising, administering a vector composition to an organism, wherein the vector composition comprises a colloidal metal particle, at least one agent, and PEG derivative.

### Claim 9 (depends on 8)

The method of claim 8, wherein the composition further comprises a targeting molecule.

### Claim 10 (depends on 8)

The method of claim 8, wherein the composition further comprises an integrating molecule.

### Claim 11 (depends on 8)

The method of claim 8, wherein the at least one agent is TNF, tumor necrosis factor.

### Claim 12 (depends on 8)

The method of claim 8, wherein the PEG derivative is a thiol derivative.

### Claim 13

A method for treating a solid tumor, comprising, administering to an organism having a solid tumor, a vector composition comprising a colloidal metal particle, at least one agent, and PEG derivative.

### Claim 14 (depends on 13)

The method of claim 13, wherein the composition further comprises a targeting molecule.

### Claim 15 (depends on 13)

The method of claim 13, wherein the composition further comprises an integrating molecule.

### Claim 16 (depends on 13)

The method of claim 13, wherein the at least one agent is TNF, tumor necrosis factor.

### Claim 17 (depends on 13)

The method of claim 13, wherein the PEG derivative is a thiol derivative.

### Claim 18 (depends on 13)

The method of claim 13, further comprising administering an anti-cancer after administering the vector composition.

### Claim 19 (depends on 13)

The method of claim 13, further comprising administering an anti-cancer before administering the vector composition.

### Claim 20 (depends on 13)

The method of claim 13, further comprising administering an anti-cancer concomitantly administering the vector composition.
